Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease

Next Previous
X
Search
Trial Profile

A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemvidutide (Primary)
  • Indications Non-alcoholic fatty liver disease; Obesity
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Altimmune

    • Most Recent Events

    • 15 Nov 2024 According to an Altimmune media release, new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease at The Liver Meeting of the American Association for the Study of Liver Diseases.
    • 15 Nov 2024 Results presented in the Altimmune Media Release.
    • 15 Oct 2024 According to an Altimmune media release, data from this study will be presented at The Liver Meeting 2024 of the American Association for the Study of Liver Diseases (AASLD) in San Diego, CA taking place November 15-19, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top